UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): December 17, 2020
Verastem, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware | 001-35403 | 27-3269467 | ||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
117 Kendrick Street, Suite 500, Needham, MA | 02494 |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (781) 292-4200
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Common stock, $0.0001 par value per share | VSTM | The Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01. Other Events
On December 17, 2020, Verastem, Inc. (the “Company”) posted a presentation, which the Company will be presenting at the BTIG Healthcare Webcast Series, Low Grade Serous Ovarian Cancer - Treatment Landscape, Unmet Need, and the Potential Role of Emerging Combination Approaches Focused on KRAS Mutations (the “Presentation”), discussing VS-6766 and defactinib treatment for low-grade serous ovarian cancer and other solid tumors. A copy of the Presentation is furnished hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits
Exhibit No. | Description | |
99.1 | Presentation for BTIG Healthcare Webcast Series | |
104 | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
VERASTEM, INC. | ||
Date: December 17, 2020 | By: | /s/ Brian M. Stuglik |
Brian M. Stuglik | ||
Chief Executive Officer |